United States was Regeneron Pharmaceuticals’s largest region in fiscal 2024, bringing in $11.94B of $15.60B (77%).
| Geography | FY 2016 | FY 2018 | FY 2021 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|
| United States | $23.24B | $11.77B | $11.94B | ||
| Non-Us | — | $870.80M | $3.67B | ||
| Outside United States | $2.71B | — | — | ||
| Total | $25.95B | $12.64B | $15.60B |
Regeneron Pharmaceuticals brought in $15.60B from its two regions in fiscal 2024, the year ended December 31, 2024. That was up 23.4% from $12.64B in fiscal 2023. United States was the largest at $11.94B (76.5%), ahead of Non-Us at $3.67B (23.5%).
Compared with fiscal 2023, Non-Us grew 320.9% to $3.67B and United States grew 1.4% to $11.94B.
Regeneron Pharmaceuticals began breaking out Non-Us in fiscal 2023, when it brought in $870.80M. Regeneron Pharmaceuticals stopped reporting Outside United States as a separate region after fiscal 2021, when it brought in $2.71B.
As Previously Reported was Regeneron Pharmaceuticals’s largest revenue line in fiscal 2018, bringing in $15.64B of $12.43B (126%).
| Restatement | FY 2018 |
|---|---|
| As Previously Reported | $15.64B |
| Adjustments | -$3.21B |
| Total | $12.43B |
Regeneron Pharmaceuticals brought in $12.43B from its two revenue lines in fiscal 2018, the year ended December 31, 2018. As Previously Reported was the largest at $15.64B (125.8%).
The total is net of Adjustments, which took $3.21B off revenue in fiscal 2018.
Collaboration Revenue was Regeneron Pharmaceuticals’s largest revenue line in fiscal 2021, bringing in $6.15B of $6.99B (88%).
| Income Statement Location | FY 2021 |
|---|---|
| Collaboration Revenue | $6.15B |
| Sga Expense | $568.40M |
| (Rd Expense)/Reduction Of Rd Expense | $10.40M |
| Cost Of Goods Sold | $253.20M |
| Other Operating Income | $12.20M |
| Total | $6.99B |
Regeneron Pharmaceuticals brought in $6.99B from its five revenue lines in fiscal 2021, the year ended December 31, 2021. Collaboration Revenue was the largest at $6.15B (87.9%), ahead of Sga Expense at $568.40M (8.1%) and Cost Of Goods Sold at $253.20M (3.6%). The other two revenue lines brought in $22.60M combined.
Regeneron Pharmaceuticals (REGN) reports its revenue by geography, by restatement and by income statement location. In fiscal 2024, United States was its largest region, bringing in $11.94B (76.5% of the total), followed by Non-Us at $3.67B (23.5%).
United States was Regeneron Pharmaceuticals' largest region in fiscal 2024, bringing in $11.94B, or 76.5% of the $15.60B total across its two regions.
As Previously Reported was Regeneron Pharmaceuticals' largest revenue line in fiscal 2018, bringing in $15.64B, or 125.8% of the $12.43B total across its two revenue lines.
Non-Us grew faster than United States in fiscal 2024, up 320.9% from $870.80M to $3.67B. United States grew 1.4% to $11.94B.
Every figure comes from Regeneron Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Regeneron Pharmaceuticals gives it, and years follow its fiscal calendar.
Regeneron Pharmaceuticals' revenue by geography goes back to fiscal 2016, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.